Hip replacement
Conditions
Interventions
Experimental Group (Oseltidine Group):A loading dose was administered 20 minutes before the end of surgery. In the experimental group, 1.5 mg of Oseltidine was given via intravenous injection, followe
Control Group (Hydromorphone Group):Control Group (Hydromorphone Group): A loading dose was administered 20 minutes before the end of surgery. In the control group, 0.8 mg of hydromorphone was given v
Sponsors
People's Hospital of Jizhou District, Tianjin
Eligibility
Sex/Gender
All
Age
65 Years to 85 Years
Inclusion criteria
Inclusion criteria: (1) Signed informed consent form; (2) Patient classified as ASA I–III; (3) Age 65–85 years; (4) Use of PCIA for postoperative analgesia; (5) Basic liver and kidney function within normal range; (6) Commitment to comply with the study protocol and participate throughout the entire study.
Exclusion criteria
Exclusion criteria: (1) Presence of severe comorbidities, such as significant cardiopulmonary insufficiency or abnormal liver and kidney function; (2) Recent use of sedative drugs within the past week; (3) Known allergy to opioids; (4) History of severe dependence on anesthetic drugs or substance abuse; (5) ASA classification of IV; (6) Cognitive impairment or mental illness; (7) Patients unwilling to participate in follow-up; (8) Current participation in other clinical studies.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| NRS score;Area Under the Curve (AUC) for NRS (Static/Dynamic);;Incidence of moderate to severe pain within 48 hours after surgery; | — |
Secondary
| Measure | Time frame |
|---|---|
| Analgesic relief rate within 24h and 48h after loading dose;PCA press times;Amount of opioid medication used;Quality of recovery at day 1 and day 3 after surgery (QoR-15 scale).; | — |
Countries
China
Contacts
Public ContactYandong Huang
People's Hospital of Jizhou District, Tianjin
Outcome results
None listed